After a year that saw Ikena Oncology trim back its workforce and pipeline, the oncology biotech thinks it has found a sustainable path forward via a merger into privately owned immunology company Inmagene Biopharmaceuticals.
https://www.fiercebiotech.com/biotech/ikena-after-tough-year-layoffs-merges-inmagene-focus-dermatitis-prospect